Arcis Biotechnology is a chemistry-based producer of critical components used in lab tests and in the products of other companies.  Arcis’ chemistry simplifies sample preparation workflows, from collection, viral inactivation, transport, extraction of nucleic acids from cells, and preparation for analysis. 

By removing steps from workflows Arcis expands capacity, reduces costs of equipment and kits, improves consistency of results with lower operating skill requirements and training.  Arcis has been adopted by the military for the detection of biothreats and has introduced chemistry-based products that simplify viral inactivation, transport and sample preparation for SARS-CoV-2 testing.  Arcis is expanding its presence in fast-growing molecular analysis markets in research, diagnostics, and pharma.

Arcis is ISO 13485 certified, has introduced CE-IVD marked products, and is institutionally funded by Calculus Capital.

Nick Ecos


Before joining Arcis Nick was CEO of Biomatrica where he led the development of biomarker collection products and the subsequent sale of the company to Exact Sciences Corporation.  He previously spent over 20 years with Life Technologies (now Thermo Fisher Scientific) as Vice President and General Manager of several global business units supplying pharma and diagnostics companies with instrument and reagent components for their gene and cell therapies and diagnostic systems.  Earlier roles included Vice President of Sales, Americas of Upstate Biotechnology (now Millipore Sigma) and before that, General Manager, Latin America of Invitrogen (now Thermo Fisher Scientific).  He holds an MBA from Harvard Business School and a B.S. from Ohio State University.

Dr Francesco Crea

Chief Technology Officer

Dr Crea joined Arcis in June, 2020.  He most recently served as Director of Innovation and Novel Technologies at Yourgene Health (formerly Premaitha Health).  He had previously served Yourgene Health as Lead Scientist and became co-inventor of their IONA Test.  Previously he joined a team at Zoragen Biotechnologies to develop a non-invasive pre-natal test, and moved with the merger to Premaitha Health.  Prior to Zoragen he was a scientist at Oxford Immunotec. Dr Crea holds a PhD in Biotechnology from the University of Birmingham, UK, and was a Research Fellow at Warwick University.

Dr Paul Reeves

Director of R&D

Dr Reeves joined Arcis in 2015.  He is a co-inventor of the company’s patents and has led the company’s most successful technical collaborations with clients.  He was previously with Genedrive (formerly Epistem) delivering projects to the US Department of Defense and developing diagnostic platform hardware and molecular assays. Earlier Paul was with QIAGEN on a team that delivered the Therascreen range of in vitro diagnostics though the FDA PMA process and launch. Dr Reeves holds an Executive MBA from Cranfield University and a PhD in Molecular Biology from the University of Liverpool